None

None

- current symptoms are fully explained by major depressive disorder or bipolar disorder. - pre-existing conditions that may cause cognitive impairment, or symptoms similar to those seen in post-covid-19 syndrome (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome [cfs]/ encephalitis meningitis [em]), as assessed by mini international neuropsychiatric interview (mini) 7.0.2. - inability to follow study procedures. - known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated inefficacy. - not currently taking any other antidepressant in the past 4 weeks. - current alcohol or substance use disorder. - inability to provide consent. - current alcohol and/or substance use disorder as confirmed by the m.i.n.i 7.0.2 - presence of comorbid psychiatric disorder that is a primary focus of clinical concern as confirmed by the m.i.n.i. 7.0.2. - medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants). - any medication for a general medical disorder that, in the opinion of the investigator, may affect cognitive function. - use of benzodiazepines within 12 hours of cognitive assessments. - consumption of alcohol within 8 hours of cognitive assessments. - physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments. - diagnosed reading disability or dyslexia. - clinically significant learning disorder by history. - electroconvulsive therapy (ect) in the last 6 months. - history of moderate or severe head trauma (e.g., loss of consciousness for >1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system. - pregnant and/or breastfeeding. - received investigational agents as part of a separate study within 30 days of the screening visit.

- current symptoms are fully explained by major depressive disorder or bipolar disorder. - pre-existing conditions that may cause cognitive impairment, or symptoms similar to those seen in post-covid-19 syndrome (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome [cfs]/ encephalitis meningitis [em]), as assessed by mini international neuropsychiatric interview (mini) 7.0.2. - inability to follow study procedures. - known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated inefficacy. - not currently taking any other antidepressant in the past 4 weeks. - current alcohol or substance use disorder. - inability to provide consent. - current alcohol and/or substance use disorder as confirmed by the m.i.n.i 7.0.2 - presence of comorbid psychiatric disorder that is a primary focus of clinical concern as confirmed by the m.i.n.i. 7.0.2. - medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants). - any medication for a general medical disorder that, in the opinion of the investigator, may affect cognitive function. - use of benzodiazepines within 12 hours of cognitive assessments. - consumption of alcohol within 8 hours of cognitive assessments. - physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments. - diagnosed reading disability or dyslexia. - clinically significant learning disorder by history. - electroconvulsive therapy (ect) in the last 6 months. - history of moderate or severe head trauma (e.g., loss of consciousness for >1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system. - pregnant and/or breastfeeding. - received investigational agents as part of a separate study within 30 days of the screening visit.